L’essai de phase 3 Zenith, chez des adultes à haut risque atteints d’hypertension artérielle pulmonaire (HTAP) et recevant la ...

The main message is that absolute levels of Lp(a) matter more than which genes may have caused them, Robert Clarke says.

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

It's among the first approved cholesterol-lowering therapies specifically for this genetic risk factor said to affect 20% of ...

Your cholesterol levels mean more than you think, especially if you have conditions like obesity or diabetes. The Centers for ...

Around Three-Fourths of Losses Suffered Were in The Middle East, South Asia, East Asia, and the Pacific While the chemicals, called phthalates, are in widespread use globally, the Middle East, South ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month ...

Heart disease. This conversation drills down on the unique challenges men face, particularly within the Black community.

A groundbreaking experimental medication called lepodisiran is showing extraordinary promise in clinical trials, potentially opening a new chapter in heart disease prevention. Lipoprotein(a ...

Eli Lilly is working on Lepodisiran, while Amgen is also doing trials for Olpasiran. The world's top pharmaceutical companies are developing drugs to lower a type of cholesterol common among ...

Though not yet available, lepodisiran could become a breakthrough treatment for a major cause of heart disease and stroke. An experimental drug seems to nearly eliminate a major—but often ...